Xiong Wen, Liu Hongxia, Xiang Bo, Shang Guangyu
Department of Nephrology, First Affiliated Hospital of Jishou University Jishou 416000, Hunan, China.
Am J Transl Res. 2024 Jul 15;16(7):3405-3412. doi: 10.62347/VYSW5854. eCollection 2024.
To investigate the effect of Liraglutide in conjunction with routine therapy on renal function, renal fibrosis, immune status, and prognosis in patients with diabetes mellitus.
The clinical data of patients with Type 2 diabetes mellitus (T2DM) treated at the First Affiliated Hospital of Jishou University from March 2021 to March 2022 were retrospectively analyzed. Patients were assigned into a control group (n=42) and a study group (n=42) according to their treatment regimen. The control group received routine treatment, and the study group received Liraglutide in addition to routine treatment. The therapeutic effects, blood glucose levels, renal function, renal fibrosis, and Immunoglobulin (Ig) levels as well as the incidence of adverse reactions, were compared between the two groups.
The effective rate was higher in study group (97.62%) than that of the control group (78.57%) (P<0.05). After treatment, the fasting blood-glucose (FBG), 2-hour postprandial plasma glucose (2hPG), and glycosylated hemoglobin (HbA1c) levels were decreased; and the study group displayed a significantly lower blood glucose level than the control group (all P<0.05). Also, the serum creatinine (Scr), blood urea nitrogen (BUN), and 24-hour urinary protein quantification (24h-UPor) were decreased after treatment; and the study group showed more pronounced improvement in renal function index than did the control group (all P<0.05). The levels of IgA, IgM, and IgG were increased after treatment compared to pre-treatment; and the study group exhibited significantly better improvement than the control group (all P<0.05). However, the study group reported a notably higher incidence of adverse reactions than the control group (19.05% vs 2.38%; P<0.05).
Liraglutide combined with routine therapy is effective in treating patients with diabetes, which can effectively reduce the levels of blood glucose andurinary protein, and the degree of renal fibrosis, while improving renal and immune functions and the clinical prognosis of diabetic patients.
探讨利拉鲁肽联合常规治疗对糖尿病患者肾功能、肾纤维化、免疫状态及预后的影响。
回顾性分析2021年3月至2022年3月在吉首大学第一附属医院接受治疗的2型糖尿病（T2DM）患者的临床资料。根据治疗方案将患者分为对照组（n = 42）和研究组（n = 42）。对照组接受常规治疗，研究组在常规治疗基础上联合使用利拉鲁肽。比较两组的治疗效果、血糖水平、肾功能、肾纤维化、免疫球蛋白（Ig）水平以及不良反应发生率。
研究组有效率（97.62%）高于对照组（78.57%）（P < 0.05）。治疗后，空腹血糖（FBG）、餐后2小时血糖（2hPG）和糖化血红蛋白（HbA1c）水平降低；研究组血糖水平显著低于对照组（均P < 0.05）。此外，治疗后血清肌酐（Scr）、血尿素氮（BUN）和24小时尿蛋白定量（24h-UPor）降低；研究组肾功能指标改善比对照组更明显（均P < 0.05）。治疗后IgA、IgM和IgG水平较治疗前升高；研究组改善明显优于对照组（均P < 0.05）。然而，研究组不良反应发生率明显高于对照组（19.05%对2.38%；P < 0.05）。
利拉鲁肽联合常规治疗对糖尿病患者有效，可有效降低血糖和尿蛋白水平以及肾纤维化程度，同时改善糖尿病患者的肾脏和免疫功能及临床预后。
